Brief: Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca

SAWAI group

30/10/2017 16:22

Oct 30 (Reuters) - Upsher-Smith Laboratories LLC: 
    * Upsher-Smith Laboratories says co's parent Sawai 
Pharmaceutical 
entered agreement with AstraZeneca to manufacture & market 
migraine medication in Japan 
    * Upsher-Smith Laboratories - agreement is to manufacture, 
market Zomig (zolmitriptan) Tablets 2.5 mg & Zomig 
(zolmitriptan) Rapid Melt (RM) Tablets 2.5 mg 
    * Upsher-Smith Labs - under agreement, Sawai expected to 
take 
manufacturing, marketing of Zomig products in Japan by mid-2018 
from AstraZeneca K.K 
 
Source text for Eikon:  ID:nPn75mpxDa  
Further company coverage:  4555.T  AZN.L  
 
 ((Bangalore.newsroom@thomsonreuters.com;))